SCHEMBL22014103

SCHEMBL22014103

c1ccc(-c2ccc(CN3CCNCCNCC3)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.76
CXCR4 P61073 10/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
CHRM2 P08172 1/20 0.64
CHRM1 P11229 1/20 0.64
ADRA2C P18825 1/20 0.64
CCR2 P41597 1/20 0.64
CXCL12 P48061 1/20 0.64
BLM P54132 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
HRH3 Q9Y5N1 1/20 0.64
CYP2C19 P33261 2/20 0.58
CYP2D6 P10635 1/20 0.58
HDAC1 Q13547 1/20 0.56
CHKA P35790 1/20 0.55
ALDH1A1 P00352 2/20 0.54
TSHR P16473 2/20 0.54
CYP2C9 P11712 1/20 0.54
HIF1A Q16665 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20676124 1.00 SIGMAR1 (0.76) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL3142583 0.98 SIGMAR1 (0.79) SIGMAR1CXCR4MEN1KMT2ACHRM2
Hydrochloric Acid SCHEMBL2235130 0.96 SIGMAR1 (0.76) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL5651043 0.92 CXCR4 (0.73) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL7062479 0.89 SIGMAR1 (0.96) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL10063607 0.89 SIGMAR1 (0.96) SIGMAR1CXCR4MEN1KMT2ACHRM2
Piperazine SCHEMBL28115310 0.89 SIGMAR1 (0.96) SIGMAR1CXCR4MEN1KMT2ACHRM2
SCHEMBL9538814 0.87 SIGMAR1 (0.92) SIGMAR1CXCR4MEN1KMT2ACHRM2
Hydrochloric Acid SCHEMBL8034018 0.87 SIGMAR1 (0.92) SIGMAR1CXCR4MEN1KMT2ACHRM2
Bromide SCHEMBL21961924 0.87 SIGMAR1 (0.92) SIGMAR1CXCR4MEN1KMT2ACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-31 US disclosed
WO-2020102820-A1 COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups SLC40A1, TAC3, ABCB7 SIGMAR1 1907/4885CXCR4 3633/4885MEN1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.